Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (121-130 of 302) with videos related to

Pageof 31
Sort By:
Cancers|February 25, 2022
Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60Dean A Regier, Brandon Chan, Sarah Costa, et al.
Plos One|May 26, 2018
The Super-Seniors Study: Phenotypic characterization of a healthy 85+ populationJulius Halaschek-Wiener, Lauren C Tindale, Jennifer A Collins, et al.
BMC Medical Genetics|November 18, 2009
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphomaJohanna M Schuetz, Amy C MaCarthur, Stephen Leach, et al.
Blood Advances|March 8, 2021
Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclinesAlden A Moccia, Kimberly Schaff, Ciara Freeman, et al.
Blood|November 16, 2006
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPLaurie H Sehn, Brian Berry, Mukesh Chhanabhai, et al.
Cancer|January 15, 2005
The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer AgencyTamara N Shenkier, Nicholas Voss, Mukesh Chhanabhai, et al.
Leukemia & Lymphoma|June 20, 2007
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphomaKenneth S Wilson, Laurie H Sehn, Brian Berry, et al.
Blood|April 10, 2014
Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysisKatharine H Xing, Joseph M Connors, Anky Lai, et al.
Leukemia & Lymphoma|April 22, 2023
Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, CanadaRania S Khelifi, Steven J Huang, Kerry J Savage, et al.
British Journal of Haematology|December 17, 2016
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphomaMatko Kalac, Jennifer K Lue, Emily Lichtenstein, et al.
Pageof 31

Showing results (121-130 of 302) with videos related to

Sort By:
Pageof 31
Cancers|February 25, 2022
Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60Dean A Regier, Brandon Chan, Sarah Costa, et al.
Plos One|May 26, 2018
The Super-Seniors Study: Phenotypic characterization of a healthy 85+ populationJulius Halaschek-Wiener, Lauren C Tindale, Jennifer A Collins, et al.
BMC Medical Genetics|November 18, 2009
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphomaJohanna M Schuetz, Amy C MaCarthur, Stephen Leach, et al.
Blood Advances|March 8, 2021
Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclinesAlden A Moccia, Kimberly Schaff, Ciara Freeman, et al.
Blood|November 16, 2006
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPLaurie H Sehn, Brian Berry, Mukesh Chhanabhai, et al.
Cancer|January 15, 2005
The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer AgencyTamara N Shenkier, Nicholas Voss, Mukesh Chhanabhai, et al.
Leukemia & Lymphoma|June 20, 2007
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphomaKenneth S Wilson, Laurie H Sehn, Brian Berry, et al.
Blood|April 10, 2014
Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysisKatharine H Xing, Joseph M Connors, Anky Lai, et al.
Leukemia & Lymphoma|April 22, 2023
Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, CanadaRania S Khelifi, Steven J Huang, Kerry J Savage, et al.
British Journal of Haematology|December 17, 2016
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphomaMatko Kalac, Jennifer K Lue, Emily Lichtenstein, et al.
Pageof 31